Read this manager's filing book
Disclosed positions
Lion Point Capital, LP: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- CUE BIOPHARMA INC
- Ticker
- CUE
- Class
- COM
- Reported value
- $1,670,408
- Reported amount
- 52,928
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001013594-26-000908Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| CUE BIOPHARMA INC | CUE | COM | $1,670,408 | 52,928 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $1,489,816 | 4,450 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $1,314,225 | 67,500 | SH | None |
| FENNEC PHARMACEUTICALS INC | FENC | COM | $1,208,666 | 112,434 | SH | None |
| ROYALTY PHARMA PLC | RPRX | SHS CLASS A | $1,199,898 | 21,400 | SH | None |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $1,132,000 | 80,000 | SH | None |
| MILESTONE PHARMACEUTICALS IN | MIST | COM | $1,098,800 | 820,000 | SH | None |
| BENITEC BIOPHARMA INC | BNTC | COM NEW | $829,560 | 62,000 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $786,960 | 36,000 | SH | None |
| BIOHAVEN LTD | BHVN | COM | $769,296 | 51,700 | SH | None |
| GERON CORP | GERN | COM | $739,840 | 578,000 | SH | None |
| UNIQURE NV | QURE | SHS | $677,082 | 14,700 | SH | None |
| ARDELYX INC | ARDX | COM | $656,115 | 128,650 | SH | None |
| LANTHEUS HLDGS INC | LNTH | COM | $610,170 | 5,500 | SH | None |
| DISC MEDICINE INC | IRON | COM | $592,434 | 8,100 | SH | None |
| SAREPTA THERAPEUTICS INC | SRPT | COM | $512,145 | 28,500 | SH | None |
| HUMACYTE INC | HUMA | COM | $507,260 | 650,000 | SH | None |
| KURA ONCOLOGY INC | KURA | COM | $504,620 | 46,000 | SH | None |
| VIATRIS INC | VTRS | COM | $439,876 | 27,700 | SH | None |
| DYNE THERAPEUTICS INC | DYN | COM | $399,780 | 18,000 | SH | None |
| BRIDGEBIO PHARMA INC | BBIO | COM | $372,400 | 5,000 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $369,733 | 9,100 | SH | None |
| PACIRA BIOSCIENCES INC | PCRX | COM | $342,495 | 13,500 | SH | None |
| REGENXBIO INC | RGNX | COM | $318,668 | 26,600 | SH | None |
| ROCKET PHARMACEUTICALS INC | RCKT | COM | $294,120 | 86,000 | SH | None |
| JANUX THERAPEUTICS INC | JANX | COM | $291,840 | 19,000 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $283,290 | 10,500 | SH | None |
| GH RESEARCH PLC | GHRS | ORDINARY SHARES | $274,176 | 10,200 | SH | None |
| SERES THERAPEUTICS INC | MCRB | COM NEW | $249,087 | 31,570 | SH | None |
| AZENTA INC | AZTA | COM | $247,544 | 9,700 | SH | None |
| JASPER THERAPEUTICS INC | JSPR | COM NEW | $195,765 | 465,000 | SH | None |
| INNOVIVA INC | INVA | COM | $186,222 | 8,200 | SH | None |
| INNATE PHARMA S A | IPHA | SPONSORED ADS | $149,318 | 81,151 | SH | None |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | COM | $137,655 | 5,250 | SH | None |
| SPRUCE BIOSCIENCES INC | SPRB | COM NEW | $54,000 | 1,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.